THYMOSIN ALPHA 1 (3mg) broad spectrum peptide immunostimulant

Please verify the availability of the product in stock before proceeding with the order.

THYMOSIN ALPHA 1 (α1)  is a peptide fragment derived from prothymosin alfa, a protein encoded in humans by the PTMA gene. Thymosin α1 was the first of the peptides contained in the 5th fraction of thymosin isolated from calf thymus tissue, which was completely sequenced in 1976 and then synthesized. The determined concentration of thymosin α1 is also found in the blood serum of healthy people (~1 ng/ml). Unlike β-thymosins, thymosin α1 is produced from a longer precursor, prothymosin α, which is 113 amino acids long and is a 28 amino acid sequence.

The main feature of thymosins is their ability to participate in the regulation, differentiation and functioning of thymus-dependent lymphocytes (T-cells, T-lymphocytes). Thymosin α1 can induce differentiation and maturation of T-lymphocytes, inhibit T-lymphocyte apoptosis, and stimulate the immune system to differentiate T-helpers animals lacking the thymus gland. It is known to enhance cellular immunity in humans as well as in experimental animals. The latter allows us to consider thymosin α1 as a promising drug for enhancing the immune response in the treatment of various diseases.

Thymosin α1 is currently approved as an immunomodulator in more than 37 countries, including Russia, for the treatment of hepatitis B and C, and is also used to enhance the immune response in the treatment of viral infections, immunodeficiencies, HIV/AIDS, and malignant neoplasms. Thymosin α1 is most commonly used in the treatment of chronic hepatitis B and as an adjuvant in vaccines. So, clinical studies show that it can be useful in cystic fibrosis, septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, tuberculosis, acute respiratory syndrome and pulmonary infections, chronic hepatitis B and in immunodeficiency states. In addition, the possibility of using thymosin α1 in the treatment of cancer, for example, hepatocellular carcinoma, in combination with conventional chemotherapy has been studied. This approach is called immune cancer therapy and is currently considered one of the most advanced treatments.

Quantity: 3 mg

Purity: over 97%

Form: lyophilizate

Excipient: mannitol

Storage: no more than +5C

Amino acid sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser- Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu- Lys-Glu-Lys-Lys-Glu-Val-Val-Glu- Glu-Ala-Glu-Asn-OH

Synonyms: Thymosinα 1 Acetate, Thymalfasin, Zadaxin, Thymosina1, thymosinα1 bovine, Thymosinα1 bovine, Thymosin alfa 1, Thymosin alfa-1, Thymosin a1, Thymosin a-1, Thymosin α1, Thymosin alfa 1

Main area of research: immunostimulation

Molecular weight: 3108.32

Molecular formula: C₁₂₉H₂₁₅N₃₃O₅₅

Structural formula:

By purchasing Russian Peptide product samples from this site, you understand that they are for research purposes only and not for the treatment of humans or animals.

Method of application:

The products are for professional use only. Peptide products are intended for research and scientific purposes only.

Guaranteed authenticity and quality:

100% original product from RUSSIAN PEPTIDE (Russian Federation)

RUSSIAN PEPTIDE is a commercial, innovative technology-based organization providing a full range of services to the pharmaceutical, biotechnology and cosmetics industries.
The company specializes in the development of technology and production of peptides and complex organic molecules as biologically active ingredients and their intermediates, biochemical substances for in vitro research purposes, reference standards for the calibration of analytical equipment, as well as reagents for peptide synthesis.

Development and production:

RUSSIAN PEPTIDE is a commercial, innovative technology-based organization providing a full range of services to the pharmaceutical, biotechnology and cosmetics industries.